Pancreatic cancer has one of the lowest survival rates of any major cancer, with an overall 5-year relative survival rate of 13.7% across all stages. That number, drawn from the SEER database covering 2016 to 2022, represents a real improvement from a decade ago when the rate hovered around 6 to 8%. But it still means the majority of people diagnosed with this cancer face a difficult prognosis, and the outlook varies enormously depending on the stage at diagnosis, the type of tumor, and whether surgery is possible.
Why Stage at Diagnosis Matters Most
The single biggest factor in pancreatic cancer prognosis is how far the disease has spread when it’s found. Pancreatic cancer is grouped into three broad categories: localized (confined to the pancreas), regional (spread to nearby lymph nodes or tissues), and distant (spread to other organs like the liver or lungs).
Localized tumors carry the best outlook by far, but they’re also the rarest at diagnosis. Only about 10 to 15% of people are diagnosed at this early stage, largely because the pancreas sits deep in the abdomen and early tumors cause few symptoms. Regional disease, where the cancer has grown into surrounding structures, accounts for a larger share. Distant or metastatic disease is the most common diagnosis, and it carries the poorest survival.
The challenge with pancreatic cancer is that symptoms like unexplained weight loss, new-onset back pain, jaundice, or sudden changes in blood sugar often don’t appear until the tumor has already grown significantly or spread. That late presentation is a major reason the overall survival rate remains low.
Tumor Type Makes a Significant Difference
Not all pancreatic cancers are the same, and the type of tumor dramatically changes the prognosis. The most common form, pancreatic ductal adenocarcinoma, accounts for roughly 90% of cases and carries the statistics most people see cited. It’s the aggressive type that drives the low overall survival numbers.
Pancreatic neuroendocrine tumors (pNETs) are far less common but have a significantly better outlook. According to the American Cancer Society, pNETs have a 5-year relative survival rate of 48% across all stages combined. When caught at the localized stage, pNETs have a 91% 5-year survival rate. Even regional pNETs have a 64% survival rate, and distant pNETs sit at 19%. These numbers reflect diagnoses between 2015 and 2021. If you’ve been told you have a pancreatic neuroendocrine tumor rather than adenocarcinoma, the expected course is considerably different.
How Surgery Changes the Outlook
For pancreatic ductal adenocarcinoma, surgery to remove the tumor offers the best chance at long-term survival. The problem is that only about 15 to 20% of tumors are considered resectable (removable) at the time of diagnosis. The rest have already grown into critical blood vessels or spread to distant organs, making surgery unfeasible.
For those who can have surgery and complete six months of follow-up chemotherapy afterward, the picture improves substantially. According to Johns Hopkins Medicine, patients with resected tumors who finish adjuvant chemotherapy have a median survival of about two and a half years and a 5-year survival rate around 50%. That’s a dramatic improvement over the overall 13.7% figure, and it underscores why surgical teams work to determine whether a tumor can be removed.
The difficult reality is that even after successful surgery, the majority of patients experience recurrence within two years. This high recurrence rate is why chemotherapy after surgery is standard, and why close monitoring continues long after the operation.
Factors That Influence Individual Prognosis
Beyond stage and tumor type, several other factors shape how pancreatic cancer is likely to behave in a specific person.
Tumor grade describes how abnormal the cancer cells look under a microscope. Lower-grade tumors tend to grow more slowly and carry a somewhat better prognosis than high-grade tumors, which are more aggressive.
Surgical margins matter for people who have surgery. If the surgeon can remove the tumor with a clear border of healthy tissue around it (called a negative margin), outcomes are better than when cancer cells are found at the edge of the removed tissue.
CA 19-9 levels are a blood marker that most pancreatic cancers produce. Doctors use this marker to track how the disease is responding to treatment. Falling CA 19-9 levels after treatment typically signal the tumor is shrinking, while rising levels may mean the cancer is growing or has returned. About 5 to 10% of people don’t produce this marker at all due to their blood type, which limits its usefulness for them.
Genetic mutations also play a role. People with BRCA1 or BRCA2 gene mutations, better known for their link to breast and ovarian cancers, can also develop pancreatic cancer. A Johns Hopkins study found that pancreatic cancer patients with BRCA mutations initially had worse outcomes than those without them: an average overall survival of 20.2 months compared to 27.8 months. However, BRCA-mutated tumors responded significantly better to platinum-based chemotherapy. Patients with BRCA mutations who received platinum-based treatment survived an average of 31 months, compared to 17.8 months for those on other chemotherapy and just 9.3 months for those who received no post-surgical chemotherapy. Knowing your mutation status can directly influence which treatment works best.
Prognosis for Advanced Disease
When pancreatic cancer has spread to distant organs, the prognosis is measured in months rather than years. Median survival for metastatic pancreatic adenocarcinoma with modern chemotherapy regimens generally falls between 6 and 12 months, depending on the specific treatment used and the patient’s overall health.
Multi-drug chemotherapy combinations have improved these numbers compared to older single-drug approaches. Clinical trials have reported median survival times of roughly 23 to 24 months for patients with resectable tumors treated with modern combination regimens before or after surgery. For patients with advanced disease who respond well to treatment, survival can extend beyond these medians, but for those whose tumors progress quickly, the timeline can be shorter.
Why Survival Rates Are Slowly Improving
The 5-year survival rate for pancreatic cancer has roughly doubled over the past 15 years, rising from around 6% to 13.7%. This improvement comes from several developments: better surgical techniques that allow more patients to undergo safe tumor removal, more effective chemotherapy combinations used before and after surgery, and improved supportive care that helps patients tolerate treatment longer.
Genetic testing has also opened new treatment avenues. Patients with specific mutations, including BRCA alterations, can now receive targeted therapies that didn’t exist a decade ago. Treatment before surgery (neoadjuvant therapy) is increasingly used to try to shrink tumors enough to make them removable, though meta-analyses of clinical trials have shown mixed results so far on whether this approach clearly improves overall survival compared to surgery first.
While 13.7% remains a sobering number, it represents real progress, and survival statistics reflect patients diagnosed years ago rather than those starting treatment today with the newest approaches. Individual outcomes depend heavily on the specific circumstances of the diagnosis, the tumor biology, and the treatment plan.